Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Renal cell carcinoma (RCC) primary tumor shrinkage...
Conference

Renal cell carcinoma (RCC) primary tumor shrinkage on vascular endothelial growth factor (VEGF)-targeted therapy (TT): A pooled analysis.

Abstract

629 Background: Cytoreductive nephrectomy (CRN) is an important treatment modality in patients (pts) with advanced RCC, however the role and timing in the context of VEGF-TT remains under investigation. The aim of this study is to determine the efficacy of VEGF-TT to induce primary tumor shrinkage in advanced RCC. Methods: We conducted a pooled analysis of 12 Pfizer-sponsored trials in pts with metastatic RCC treated with …

Authors

Bosse D; Lin X; Simantov R; Lalani A-KA; Derweesh I; Chang SL; Choueiri TK; McKay RR

Volume

36

Pagination

pp. 629-629

Publisher

American Society of Clinical Oncology (ASCO)

Publication Date

February 20, 2018

DOI

10.1200/jco.2018.36.6_suppl.629

Conference proceedings

Journal of Clinical Oncology

Issue

6_suppl

ISSN

0732-183X